NCT05105607View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Interventions
DRUG

D-4517.2

Subcutaneous (SC) injection

Trial Locations (1)

4006

Nucleus Network (Brisbane), Brisbane

Sponsors
All Listed Sponsors
lead

Ashvattha Therapeutics, Inc.

INDUSTRY

NCT05105607 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants | Biotech Hunter | Biotech Hunter